• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cationic Nanogel-mediated Runx2 and Osterix siRNA Delivery Decreases Mineralization in MC3T3 Cells.
CONCLUSIONS: Although mRNA and protein knockdown were confirmed as a result of RNAi treatments against Runx2 and Osx, complete elimination of mineralization processes was not achieved. RNAi targeting mid- and late-stage osteoblast differentiation markers such as ALP, osteocalcin, osteopontin, and bone sialoprotein) may produce the desired RNAi-nanogel nanostructured polymer HO prophylaxis. CLINICAL RELEVANCE: Successful HO prophylaxis should target and silence osteogenic markers critical for heterotopic bone formation processes. The identification of such markers, beyond RUNX2 and OSX, may enhance the effectiveness of...
Source: Clinical Orthopaedics and Related Research - December 2, 2014 Category: Orthopaedics Authors: Shrivats AR, Hsu E, Averick S, Klimak M, Watt AC, DeMaio M, Matyjaszewski K, Hollinger JO Tags: Clin Orthop Relat Res Source Type: research

MicroRNA Regulates Vascular Endothelial Growth Factor Expression in Chondrosarcoma Cells.
CONCLUSIONS: miR-181a is a hypoxia-regulated microRNA that is overexpressed in chondrosarcoma and enhances VEGF expression, an effect that could be inhibited by anti-miR-181a. CLINICAL RELEVANCE: Systemic treatment options for chondrosarcoma are limited. Antiangiogenic strategies could potentially be effective in limiting tumor progression. One method of inhibiting VEGF expression and associated angiogenesis could be an antagomir-based therapy targeted at miR-181a or other oncogenic microRNAs, although methods of systemic delivery are still under development. The effectiveness of antagomirs also needs to be compared w...
Source: Clinical Orthopaedics and Related Research - August 9, 2014 Category: Orthopaedics Authors: Sun X, Wei L, Chen Q, Terek RM Tags: Clin Orthop Relat Res Source Type: research